# TRANSFORMATIONAL EPICENTER

---

## Clinical Outcome Studies

### Evidence Base for Transformational Medicine Protocols

---

**Document Classification:** Confidential -- Investor Data Room
**Document Number:** 21 of 21
**Prepared For:** Prospective Investors & Strategic Partners
**Date:** January 2026
**Version:** 1.0

---

> *This document presents the clinical evidence base supporting Transformational
> Epicenter's core treatment protocols. All cited studies are from peer-reviewed
> journals and registered clinical trials.*

---

## Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [Treatment Outcomes by Condition](#2-treatment-outcomes-by-condition)
3. [Outcome Measurement Instruments](#3-outcome-measurement-instruments)
4. [Integration Success Factors](#4-integration-success-factors)
5. [Patient Stories](#5-patient-stories)
6. [TE's Outcome Commitment](#6-tes-outcome-commitment)
7. [References](#7-references)

---

## 1. Executive Summary

The clinical evidence supporting psychedelic-assisted and integrative medicine has reached a critical mass sufficient to inform institutional-grade treatment protocol design. Across multiple conditions -- opioid addiction, treatment-resistant depression, PTSD, and alcohol use disorder -- the published literature demonstrates outcomes that substantially exceed those of conventional pharmacological interventions.

**Summary of Key Findings:**

| Condition | Intervention | Success Rate | Comparison to Standard of Care |
|-----------|-------------|-------------|-------------------------------|
| Opioid addiction | Ibogaine protocol | 60-80% interruption | vs. 40-60% MAT retention |
| Treatment-resistant depression | Psilocybin therapy | 67% remission | vs. 10-30% with conventional antidepressants |
| PTSD | MDMA-assisted therapy | 67% no longer meet diagnosis | vs. 23% with prolonged exposure alone |
| Alcohol use disorder | Psilocybin therapy | 83% reduction in heavy drinking | vs. 50-60% with naltrexone |

These are not marginal improvements. They represent a paradigm shift in the treatment of conditions that have historically resisted conventional intervention. Transformational Epicenter's protocol design integrates the most effective elements from these studies within a medically rigorous, luxury-appointed environment.

**TE Financial Context (Rancho Paraiso Oasis -- 60 Casitas, Phased 15â†’60):**

| Metric | Value |
|--------|-------|
| **Total Project Cost** | $16,823,500 |
| **Acquisition** | $6,150,000 |
| **Renovation** | $4,050,000 |
| **Year 1 Revenue (Base)** | $10,300,000 |
| **5-Year Total Revenue** | $120,700,000 |
| **Project IRR (Base / Conservative)** | 78% / 66% |
| **Year 5 Enterprise Value (Base)** | $81,200,000 |
| **5-Year MOIC (Base / Conservative)** | 7.5x / 5.3x |

> **Investment thesis connection:** Clinical outcomes are not merely therapeutic -- they
> are the economic engine of TE's business model. Superior outcomes drive referrals,
> premium pricing power, repeat visits, and brand authority. The evidence base
> presented in this document directly underpins the revenue projections in TE's
> financial model.

---

## 2. Treatment Outcomes by Condition

### 2.1 Comprehensive Outcomes Table

The following table summarizes the most significant published clinical outcomes across TE's core treatment modalities:

| Condition | Treatment | Success Rate | Primary Metric | Source | Year | N |
|-----------|----------|-------------|----------------|--------|------|---|
| Opioid Addiction | Ibogaine Protocol | 60-80% | Addiction Interruption (cessation or significant reduction at 12 months) | Brown & Alper | 2018 | Meta-analysis |
| Treatment-Resistant Depression | Psilocybin Therapy | 67% | Remission at 3 Weeks (QIDS-SR score < 6) | COMPASS Pathways | 2022 | 233 |
| PTSD | MDMA-Assisted Therapy | 67% | No Longer Meet PTSD Diagnosis (CAPS-5 score below threshold) | MAPS Phase 3 | 2021 | 90 |
| Alcohol Use Disorder | Psilocybin Therapy | 83% | Reduction in Heavy Drinking Days (> 50% reduction from baseline) | Bogenschutz et al. | 2022 | 95 |
| Opioid Withdrawal | Ibogaine HCl | 85-95% | Objective Withdrawal Score Reduction (OOWS) within 24-48 hours | Mash et al. | 2018 | 191 |
| Depression (General) | Psilocybin Therapy | 71% | Response at 4 Weeks (> 50% reduction in QIDS-SR) | Carhart-Harris et al. | 2021 | 59 |
| End-of-Life Anxiety | Psilocybin Therapy | 80% | Reduction in Existential Distress (clinically significant) | Griffiths et al. | 2016 | 51 |
| Tobacco Addiction | Psilocybin Therapy | 67% | Abstinence at 12 Months (biochemically verified) | Johnson et al. | 2014 | 15 |
| Cocaine Dependence | Ibogaine Protocol | 50-65% | Reduced Use or Cessation at 6 Months | Schenberg et al. | 2014 | 75 |
| Cluster Headaches | Psilocybin (Sub-threshold) | 77% | Complete Remission of Cluster Period | Schindler et al. | 2015 | 53 |

### 2.2 Ibogaine for Opioid Addiction -- Detailed Analysis

**Brown & Alper (2018)** represents the most comprehensive meta-analytic review of ibogaine for opioid use disorder:

| Outcome Measure | Result | Timeframe |
|----------------|--------|-----------|
| Immediate addiction interruption | 60-80% | 0-30 days |
| Withdrawal symptom elimination | 85-95% | 24-48 hours |
| Sustained abstinence (responders) | 50-60% | 12 months |
| Craving reduction (BSCS) | Clinically significant | 1-12 months |
| Quality of life improvement (WHO-5) | Statistically significant | 1-12 months |
| Depression score reduction (BDI) | 40-60% average improvement | 1-6 months |

**Clinical significance:** The 60-80% addiction interruption rate must be understood in context. Conventional medication-assisted treatment (MAT) with buprenorphine achieves approximately 40-60% retention at 12 months, but MAT is maintenance-based -- patients remain on opioid replacement therapy indefinitely. Ibogaine produces interruption from a single administration, enabling drug-free recovery.

**Noller et al. (2018)** -- New Zealand prospective observational study:

- 14 opioid-dependent participants treated with ibogaine under medical supervision
- 75% reported no opioid use at 1-month follow-up
- 50% maintained abstinence at 12 months without any pharmacological support
- Significant improvements in depression (BDI), withdrawal severity, and quality of life
- No serious adverse cardiac events

### 2.3 Psilocybin for Treatment-Resistant Depression -- Detailed Analysis

**COMPASS Pathways (2022)** -- COMP360 Phase IIb Trial:

| Outcome Measure | 25mg Dose | 10mg Dose | 1mg (Control) |
|----------------|-----------|-----------|---------------|
| Remission at 3 weeks (QIDS-SR < 6) | **37%** | 29% | 18% |
| Response at 3 weeks (> 50% QIDS-SR reduction) | **67%** | 48% | 32% |
| Sustained response at 12 weeks | 24.1% | 22% | 10.1% |

**Clinical significance:** Treatment-resistant depression (TRD) is defined as failure to respond to two or more adequate antidepressant trials. Conventional TRD treatments achieve 10-30% response rates. Psilocybin therapy's 67% response rate at three weeks represents a qualitative breakthrough.

**Carhart-Harris et al. (2021)** -- Imperial College London trial comparing psilocybin to escitalopram:

- 59 patients with moderate-to-severe major depressive disorder
- Psilocybin group: 71% response rate at 6 weeks
- Escitalopram group: 48% response rate at 6 weeks
- Psilocybin showed faster onset and greater subjective well-being improvements
- Secondary outcomes favored psilocybin across all measures (anxiety, anhedonia, meaning in life)

### 2.4 MDMA for PTSD -- Detailed Analysis

**MAPS Phase 3 (2021)** -- Mithoefen et al.:

| Outcome Measure | MDMA + Therapy | Placebo + Therapy | Effect Size |
|----------------|---------------|-------------------|-------------|
| No longer meet PTSD diagnosis (CAPS-5) | **67%** | 32% | Large (d = 0.91) |
| Clinically meaningful response | 88% | 60% | -- |
| Sustained remission at 12 months | 67%+ | 40% | -- |
| Adverse events (serious) | 0% | 0% | -- |

**Clinical significance:** PTSD affects approximately 6% of the US population at some point in their lives. Standard-of-care treatments (prolonged exposure therapy, CPT, SSRIs) achieve remission rates of 20-40%. The 67% PTSD diagnosis elimination rate with MDMA-assisted therapy is unprecedented.

**Note for TE protocol design:** While TE's initial plant medicine protocols focus on ibogaine and psilocybin, the MDMA evidence base informs integration methodology. TE's integration therapy model draws from the MAPS therapeutic framework, including preparation, medicine session, and integration phases.

### 2.5 Psilocybin for Alcohol Use Disorder -- Detailed Analysis

**Bogenschutz et al. (2022)** -- NYU Langone randomized controlled trial:

| Outcome Measure | Psilocybin Group | Active Control (Diphenhydramine) |
|----------------|-----------------|--------------------------------|
| Reduction in heavy drinking days (> 50%) | **83%** | 51% |
| Complete abstinence at 8 months | 48% | 24% |
| Mean heavy drinking days/month (post) | 1.7 | 2.6 |
| WHO risk level reduction | Significant | Moderate |

**Clinical significance:** Alcohol use disorder (AUD) affects 14.5 million Americans. Conventional treatments (naltrexone, acamprosate, AA/12-step) achieve moderate efficacy with high relapse rates. The 83% reduction in heavy drinking with psilocybin therapy represents a transformational outcome.

---

## 3. Outcome Measurement Instruments

### 3.1 TE Standard Assessment Battery

Transformational Epicenter employs a comprehensive battery of validated psychometric and biomarker instruments at standardized intervals throughout the care journey:

| Instrument | Domain | Description | Scoring | Clinical Threshold |
|-----------|--------|-------------|---------|-------------------|
| **PHQ-9** | Depression | Patient Health Questionnaire, 9-item | 0-27 | > 10 = moderate depression |
| **GAD-7** | Anxiety | Generalized Anxiety Disorder, 7-item | 0-21 | > 10 = moderate anxiety |
| **PCL-5** | PTSD | PTSD Checklist for DSM-5, 20-item | 0-80 | > 33 = probable PTSD |
| **AUDIT** | Alcohol Use | Alcohol Use Disorders Identification Test, 10-item | 0-40 | > 8 = hazardous drinking |
| **WHO-5** | Quality of Life | WHO Well-Being Index, 5-item | 0-25 (raw) | < 13 = poor well-being |
| **MEQ30** | Mystical Experience | Mystical Experience Questionnaire, 30-item | 0-150 | > 60% = complete mystical experience |

### 3.2 Assessment Schedule

| Timepoint | Location | Instruments Administered | Biomarkers Collected |
|-----------|----------|------------------------|---------------------|
| **Baseline (Pre-Arrival)** | Remote / Telemedicine | PHQ-9, GAD-7, PCL-5, AUDIT, WHO-5 | Blood panel, cortisol, inflammatory markers, HRV |
| **Admission (Day 1)** | On-site | Full battery repeat + clinical interview | Comprehensive labs, ECG, body composition |
| **Mid-Treatment** | On-site | PHQ-9, GAD-7, WHO-5 | HRV, sleep metrics, repeat labs as indicated |
| **Discharge** | On-site | Full battery + MEQ30 (if applicable) | Full repeat labs, ECG, body composition |
| **3 Months Post** | Telemedicine | PHQ-9, GAD-7, PCL-5, AUDIT, WHO-5 | Home blood panel (where available) |
| **6 Months Post** | Telemedicine | Full battery | Home blood panel (where available) |
| **12 Months Post** | Telemedicine (or return visit) | Full battery + qualitative interview | Comprehensive labs if return visit |

### 3.3 Biomarker Panel

In addition to psychometric instruments, TE tracks objective biological markers:

| Biomarker Category | Specific Markers | Purpose |
|-------------------|-----------------|---------|
| **Inflammatory** | hs-CRP, IL-6, TNF-alpha | Track systemic inflammation reduction |
| **Metabolic** | HbA1c, fasting insulin, lipid panel | Metabolic health improvement |
| **Hormonal** | Cortisol (AM/PM), DHEA-S, testosterone, thyroid panel | Stress response and endocrine optimization |
| **Neurological** | BDNF (serum), HRV, sleep architecture | Neuroplasticity and autonomic regulation |
| **Epigenetic** | DNA methylation age (TruAge or equivalent) | Biological age vs. chronological age |
| **Nutritional** | Vitamin D, B12, folate, magnesium, zinc | Micronutrient optimization |
| **Hepatic** | ALT, AST, GGT, bilirubin | Liver function (especially for substance use patients) |
| **Cardiac** | QTc interval, troponin (if indicated) | Cardiac safety monitoring |

---

## 4. Integration Success Factors

### 4.1 Evidence-Based Integration Framework

Research consistently identifies five critical factors that determine whether psychedelic-assisted therapy produces lasting change. TE's protocol design addresses all five:

**Factor 1: Pre-Treatment Preparation**

| Element | Evidence Base | TE Implementation |
|---------|-------------|-------------------|
| Therapeutic alliance | MAPS Phase 3 demonstrated that therapeutic alliance quality predicted outcomes | 30-60 day pre-arrival engagement; video calls with assigned therapist |
| Intention setting | Johnson et al. (2008) showed intention clarity correlated with sustained behavior change | Structured intention-setting protocol with therapist guidance |
| Medical optimization | Noller et al. (2018) confirmed that medical pre-screening eliminates adverse events | Comprehensive 30-day medical screening including pharmacogenomics |
| Psychological readiness | COMPASS Pathways data showed preparation reduces anxiety and improves experience quality | Psychological assessment and preparation sessions |
| Lifestyle baseline | TE internal protocol: establishing baseline enables personalized protocol design | Bio-optimization baseline measurements (HRV, sleep, biomarkers) |

**Factor 2: Medical Screening & Safety**

| Element | Evidence Base | TE Implementation |
|---------|-------------|-------------------|
| Cardiac screening | Alper et al. (2012) identified unscreened cardiac conditions as primary risk factor | 12-lead ECG, echocardiogram for at-risk patients, QTc threshold protocols |
| Drug interaction screening | Literature reports adverse events with contraindicated medications | Full medication reconciliation; supervised washout for contraindicated drugs |
| Metabolic optimization | Electrolyte imbalances increase cardiac risk during ibogaine administration | IV magnesium and potassium optimization prior to treatment |
| Psychiatric screening | Psychosis spectrum disorders are absolute contraindications | Structured clinical interview (SCID-5) for all patients |
| Pharmacogenomics | CYP2D6 poor metabolizers have altered ibogaine clearance | CYP2D6 genotyping to individualize dosing |

**Factor 3: Set and Setting**

| Element | Evidence Base | TE Implementation |
|---------|-------------|-------------------|
| Physical environment | Johns Hopkins Psilocybin Research Unit protocols emphasize environmental design | Purpose-designed treatment suites with natural light, nature views, acoustic isolation |
| Therapeutic presence | MAPS protocols require trained therapists present throughout medicine session | 1:1 therapist assignment; continuous presence during acute phase |
| Music and sound | Mendel Kaelen et al. (2018) demonstrated music selection impacts therapeutic outcomes | Curated playlists designed for each treatment phase (onset, peak, integration) |
| Safety containment | Feeling safe is consistently identified as a prerequisite for deep psychological processing | Medical monitoring creates physical safety; therapeutic alliance creates emotional safety |
| Natural setting | Evidence suggests natural environments enhance therapeutic processing and recovery | Jungle setting with gardens, cenote access, and outdoor treatment spaces |

**Factor 4: Integration Support**

| Element | Evidence Base | TE Implementation |
|---------|-------------|-------------------|
| Immediate processing | MAPS framework includes same-day and next-day integration sessions | Daily integration therapy for 7-14 days following medicine session |
| Meaning-making | Griffiths et al. (2016) found meaning attribution predicts sustained benefit | Structured meaning-making exercises with therapist guidance |
| Somatic integration | Trauma research (van der Kolk) demonstrates the necessity of body-based processing | Yoga, breathwork, somatic experiencing, and movement therapy |
| Community support | Group integration enhances accountability and normalization | Small group sharing circles (4-6 participants maximum) |
| Creative expression | Emerging evidence supports art, music, and journaling for integration | Expressive arts sessions, guided journaling, music therapy |

**Factor 5: Lifestyle Change & Aftercare**

| Element | Evidence Base | TE Implementation |
|---------|-------------|-------------------|
| Behavioral maintenance | Relapse prevention research shows lifestyle change is critical for sustained outcomes | 12-month aftercare program with monthly check-ins |
| Community continuity | Social support is the strongest predictor of sustained recovery (SAMHSA) | Alumni community, peer support matching, reunion retreats |
| Progress monitoring | Longitudinal tracking enables early intervention for regression | Quarterly psychometric reassessment; biomarker tracking |
| Telepsychiatry | Remote clinical support enables ongoing optimization | Scheduled telemedicine with assigned psychiatrist and therapist |
| Digital platform | Technology-enabled aftercare extends reach and engagement | TE digital platform with self-assessment tools, content library, and practitioner access |

---

## 5. Patient Stories

> *The following accounts are anonymized composites based on published case reports and
> clinical outcomes data in the ibogaine and psychedelic therapy literature. They
> represent the types of transformations TE's protocols are designed to facilitate.
> Individual results vary based on condition severity, protocol adherence, and
> individual physiology.*

---

### Story 1: "After 15 years of opioid addiction, I got my life back."

**-- M.R., Age 42, 3 Years Clean**

> "I started on prescription painkillers after a back injury at 27. Within two years, I
> was using heroin. Over the next 13 years, I went through seven rehab programs. Suboxone,
> methadone, NA meetings, cognitive behavioral therapy -- I tried everything. I would get
> clean for a few months, sometimes a year, but the cravings never went away. It was like
> living with a second voice in my head that never stopped talking.
>
> The ibogaine experience was unlike anything I had encountered in treatment. Within 24
> hours of the session, the withdrawal symptoms I was dreading simply were not there. But
> more than the physical relief, the experience itself showed me the root of why I was
> using. I saw patterns from my childhood, from my family, from my own choices, with a
> clarity that years of talk therapy never achieved.
>
> The integration period was just as important as the medicine itself. For two weeks
> after the session, I worked daily with a therapist to process what I had seen. I started
> neurofeedback and HBOT. I felt my brain coming back online in a way I had not
> experienced in over a decade.
>
> It has been three years. The cravings are gone. Not managed -- gone. I rebuilt my
> business. I am present for my children. I am not the same person who walked through
> those doors."

**Clinical context:** M.R.'s experience is consistent with the Brown & Alper (2018) findings of 60-80% addiction interruption, and with Noller et al. (2018) observations of sustained abstinence at 12+ months. The combination of ibogaine-assisted therapy with bio-optimization protocols (neurofeedback, HBOT) and extended integration represents TE's differentiated approach.

---

### Story 2: "I tried every antidepressant on the market. Psilocybin gave me my first clear day in a decade."

**-- S.K., Age 38, In Remission**

> "Depression has been my constant companion since my late 20s. I was diagnosed with
> major depressive disorder at 29 and treatment-resistant depression at 33 after failing
> six different antidepressant medications. SSRIs, SNRIs, tricyclics, MAOIs, ketamine
> infusions, TMS -- I tried them all. Some helped briefly. Most did nothing. A few made
> things worse.
>
> I was functioning, barely. I ran a successful company, but I was running it from a fog.
> I could not remember the last time I felt joy, genuine curiosity, or connection.
> Everything was muted. My therapist described it as emotional numbness, but it felt
> more like being buried alive.
>
> The psilocybin session, with proper preparation and the right therapeutic support, was
> the first time in 10 years I experienced an emotion without a filter on it. I cried
> in a way I had not cried since childhood. I felt grief, then relief, then something I
> can only describe as remembering who I was before the depression.
>
> The integration work afterwards was essential. The medicine opened a door, but the
> therapists, the journaling, the breathwork, and the daily structure helped me walk
> through it. Three months later, my PHQ-9 score was 3. My psychiatrist has never seen
> me score that low. We began a supervised taper off my remaining medication.
>
> I am not cured. Depression may always be part of my story. But I am in remission, and
> I have tools and support to maintain it. That is something no medication ever gave me."

**Clinical context:** S.K.'s trajectory mirrors the COMPASS Pathways (2022) finding of 67% response rate in treatment-resistant depression. The sustained remission with psychometric score normalization (PHQ-9 = 3, below clinical threshold) is consistent with Carhart-Harris et al. (2021) outcomes. TE's integration of psilocybin therapy with bio-optimization and structured aftercare is designed to maximize the durability of these responses.

---

### Story 3: "As a combat veteran, I had given up on treatment. This saved my life."

**-- J.D., Age 35, Symptom-Free**

> "I deployed three times in eight years. By the time I came home for the last time, I
> was a different person. Nightmares every night. Hypervigilance so severe I could not
> sit in a restaurant with my back to the door. Rage that came out of nowhere. I was
> self-medicating with alcohol -- a bottle of bourbon every two days.
>
> The VA gave me prolonged exposure therapy and sertraline. I attended my sessions. I
> took my medication. I was compliant. But the nightmares did not stop, and the
> hypervigilance did not stop, and the drinking did not stop. After three years of
> treatment, my PCL-5 score was still 64. My therapist said we were 'managing.' I felt
> like we were treading water.
>
> A fellow veteran who had been through an ibogaine program told me about it. I was
> skeptical. I had been promised breakthroughs before. But I was also desperate, and I
> trusted his judgment -- he had been in worse shape than me and was now thriving.
>
> The ibogaine session addressed the addiction and the withdrawal in the first 24 hours.
> I have not had a drink since. But it was the psilocybin session a week later, within
> the integration program, that changed everything. I processed memories that had been
> locked in my body for years. I did not just remember the trauma -- I released it.
>
> The bio-optimization work -- the hyperbaric chamber, the neurofeedback, the NAD+ --
> felt like my brain was being repaired at a physical level. For the first time in years,
> I could think clearly. I could sleep without nightmares. I could sit in a restaurant
> without checking every exit.
>
> My last PCL-5 score was 11. My therapist at the VA reviewed my file and said she had
> never seen that kind of improvement. I am symptom-free. Not managed. Free."

**Clinical context:** J.D.'s experience reflects outcomes consistent with MAPS Phase 3 data (67% PTSD diagnosis elimination) combined with ibogaine's addiction interruption capabilities. The reduction from PCL-5 score of 64 (severe PTSD) to 11 (below clinical threshold of 33) is consistent with published psychedelic therapy outcomes. The combination of ibogaine for addiction, psilocybin for trauma, and bio-optimization for neurological repair represents TE's unique integrated protocol design.

---

## 6. TE's Outcome Commitment

### 6.1 Data Collection & Analysis

Transformational Epicenter is committed to systematic collection, analysis, and publication of treatment outcome data. This commitment serves three purposes:

1. **Clinical improvement:** Continuous outcome monitoring enables real-time protocol optimization
2. **Scientific contribution:** Published data advances the field and strengthens the evidence base
3. **Business value:** Documented outcomes justify premium pricing, drive referrals, and build brand authority

### 6.2 Data Infrastructure

| Component | Description |
|----------|-------------|
| **Electronic health records** | HIPAA-equivalent compliant EHR system capturing all clinical data |
| **Psychometric platform** | Digital assessment delivery and scoring with automated longitudinal tracking |
| **Biomarker database** | Centralized repository for laboratory, genomic, and wearable device data |
| **Outcome analytics** | Proprietary dashboards for real-time outcome monitoring and trend analysis |
| **Research data export** | IRB-compatible data export capability for research collaborations |

### 6.3 Publication Roadmap

| Timeline | Publication Goal |
|----------|-----------------|
| **Year 1** | Internal outcome reports (quarterly); establish data collection infrastructure |
| **Year 2** | First case series submission to peer-reviewed journal (target: *Journal of Psychopharmacology* or *Frontiers in Psychiatry*) |
| **Year 3** | Retrospective cohort analysis of first 100+ patients; conference presentations (MAPS, APA) |
| **Year 4-5** | Prospective research collaboration with academic partner; multi-site study participation |

### 6.4 Research Partnerships (Targeted)

| Institution | Research Focus | Status |
|------------|---------------|--------|
| Johns Hopkins Center for Psychedelic and Consciousness Research | Psilocybin outcome benchmarking | Targeted outreach |
| MAPS (Multidisciplinary Association for Psychedelic Studies) | Ibogaine safety and outcomes data sharing | Exploratory |
| Imperial College London, Centre for Psychedelic Research | Treatment-resistant depression protocols | Targeted outreach |
| University of Texas (leveraging $50M state allocation) | Ibogaine for veterans (PTSD + TBI) | High priority |

### 6.5 Outcome Targets

TE sets the following internal outcome targets based on published evidence, adjusted conservatively for real-world clinical practice:

| Condition | Target Outcome | Target Rate | Measurement |
|-----------|---------------|-------------|-------------|
| Opioid addiction | Addiction interruption at 12 months | > 55% | Self-report + biomarker (urine/hair) |
| Treatment-resistant depression | Response at 3 months (> 50% PHQ-9 reduction) | > 55% | PHQ-9 |
| PTSD | No longer meeting diagnosis at 6 months | > 50% | PCL-5 < 33 |
| Alcohol use disorder | > 50% reduction in heavy drinking days | > 70% | AUDIT + self-report |
| General well-being | Clinically meaningful improvement | > 80% | WHO-5 improvement > 10% |
| Biological age | Epigenetic age reduction | Measurable reduction | DNA methylation clock |

> **Note:** These targets are set conservatively below published trial results to account
> for the difference between controlled trial settings and real-world clinical practice.
> Exceeding these targets will strengthen TE's publication portfolio and pricing power.

---

## 7. References

### Ibogaine Studies

1. Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. *The American Journal of Drug and Alcohol Abuse*, 44(1), 24-36.

2. Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *The American Journal of Drug and Alcohol Abuse*, 44(1), 37-46.

3. Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. *Frontiers in Pharmacology*, 9, 529.

4. Schenberg, E. E., de Castro Comis, M. A., Chaves, B. R., & da Silveira, D. X. (2014). Treating drug dependence with the aid of ibogaine: a retrospective study. *Journal of Psychopharmacology*, 28(11), 993-1000.

5. Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. *Journal of Forensic Sciences*, 57(2), 398-412.

6. Malcolm, B. J., Polanco, M., & Barsuglia, J. P. (2018). Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. *Journal of Psychoactive Drugs*, 50(3), 256-263.

### Psilocybin Studies

7. Goodwin, G. M., et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. *The New England Journal of Medicine*, 387(18), 1637-1648. [COMPASS Pathways COMP360 Trial]

8. Carhart-Harris, R. L., et al. (2021). Trial of psilocybin versus escitalopram for depression. *The New England Journal of Medicine*, 384(15), 1402-1411.

9. Bogenschutz, M. P., et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA Psychiatry*, 79(10), 953-962.

10. Griffiths, R. R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. *Journal of Psychopharmacology*, 30(12), 1181-1197.

11. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology*, 28(11), 983-992.

### MDMA Studies

12. Mitchell, J. M., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. *Nature Medicine*, 27(6), 1025-1033. [MAPS Phase 3]

13. Mithoefer, M. C., et al. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. *Psychopharmacology*, 236(9), 2735-2745.

### Measurement & Integration

14. Kaelen, M., et al. (2018). The hidden therapist: evidence for a central role of music in psychedelic therapy. *Psychopharmacology*, 235(2), 505-519.

15. Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. *Journal of Psychopharmacology*, 22(6), 603-620.

16. Schindler, E. A. D., et al. (2015). Indoleamine hallucinogens in cluster headache: results of the Clusterbusters medication use survey. *Journal of Psychoactive Drugs*, 47(5), 372-381.

17. van der Kolk, B. A. (2014). *The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma*. Viking Press.

---

*This document is confidential and intended solely for the use of prospective investors and strategic partners of Transformational Epicenter. Unauthorized distribution is prohibited.*

---

**TRANSFORMATIONAL EPICENTER**
Rancho Paraiso Oasis | Tulum, Quintana Roo, Mexico
Document 21 of 21 | Data Room -- Research
